SF
KRYS icon

Synovus Financial’s Krystal Biotech KRYS Stock Holding History

Synovus Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.62M Sell
20,516
-127
-0.6% -$19K 0.04% 257
2025
Q2 		$2.84M Buy
+20,643
New +$3.03M 0.03% 286

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Synovus Financial's KRYS Position: Q3 2025 in Review

Synovus Financial reduced its Krystal Biotech (KRYS) stake by 0.62% in Q3 2025, selling an estimated $19K and leaving 20,516 shares worth $3.62M. The position accounts for 0.04% of the portfolio, ranked #257.

Synovus Financial first reported a position in KRYS in Q2 2025 and has held it in 2 quarters since. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Synovus Financial held 20,516 shares of Krystal Biotech worth $3.62M as of Q3 2025.
  • Synovus Financial sold 127 Krystal Biotech shares in Q3 2025, an estimated $19K.
  • Krystal Biotech made up 0.04% of Synovus Financial's portfolio in Q3 2025, its #257 holding.
  • Synovus Financial first reported a position in Krystal Biotech in Q2 2025 and has held it in 2 quarters since.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.